Status:
RECRUITING
Implementation of an Oral Chemotherapy Adherence Intervention
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Solid Tumor
Hematologic Malignancy
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two...
Detailed Description
Participants enrolled in this adherence program will have individualized counseling sessions with their clinical pharmacists regarding their oral anticancer agent. The pharmacists will review with all...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult (age ≥21 years-old) patients
- Diagnosed with a solid or hematologic malignancy
- Monotherapy on oral anticancer agent on treatment for at least 6 months
- Exclusion criteria:
- Patients on time-limited or intermittent therapy (non-continuous)
- Patients on comfort (end-of-life) care
- Patients enrolled on hospice
Exclusion
Key Trial Info
Start Date :
May 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2028
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06989489
Start Date
May 28 2025
End Date
August 30 2028
Last Update
July 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UNC Chapel Hill
Chapel Hill, North Carolina, United States, 27516